MedTrace Logo

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN

NCT04949503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1931

Last updated 2023-07-27

No results posted yet for this study

Summary

This study is a retrospective real-world study. In this study, we plan to collect the clinical data of LASCCHN patients who received chemoradiotherapy combined with or without nimotuzumab .

Conditions

  • Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

nimotuzumab

Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).

Sponsors & Collaborators

  • Biotech Pharmaceutical Co., Ltd.

    lead OTHER

Principal Investigators

  • Jinyi Lang · Sichuan Cancer Hospital and Research Institute

  • Chenping Zhang · Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medcine

  • Junlin Yi · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-08
Primary Completion
2023-03-15
Completion
2023-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04949503 on ClinicalTrials.gov